A CRISPR-Cas9 screen identifies essential CTCF anchor sites for estrogen receptor-driven breast cancer cell proliferation.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
10 10 2019
Historique:
accepted: 24 07 2019
revised: 11 07 2019
received: 29 01 2019
pubmed: 3 8 2019
medline: 4 12 2019
entrez: 3 8 2019
Statut: ppublish

Résumé

Estrogen receptor α (ERα) is an enhancer activating transcription factor, a key driver of breast cancer and a main target for cancer therapy. ERα-mediated gene regulation requires proper chromatin-conformation to facilitate interactions between ERα-bound enhancers and their target promoters. A major determinant of chromatin structure is the CCCTC-binding factor (CTCF), that dimerizes and together with cohesin stabilizes chromatin loops and forms the boundaries of topologically associated domains. However, whether CTCF-binding elements (CBEs) are essential for ERα-driven cell proliferation is unknown. To address this question in a global manner, we implemented a CRISPR-based functional genetic screen targeting CBEs located in the vicinity of ERα-bound enhancers. We identified four functional CBEs and demonstrated the role of one of them in inducing chromatin conformation changes in favor of activation of PREX1, a key ERα target gene in breast cancer. Indeed, high PREX1 expression is a bona-fide marker of ERα-dependency in cell lines, and is associated with good outcome after anti-hormonal treatment. Altogether, our data show that distinct CTCF-mediated chromatin structures are required for ERα- driven breast cancer cell proliferation.

Identifiants

pubmed: 31372638
pii: 5542888
doi: 10.1093/nar/gkz675
pmc: PMC6765117
doi:

Substances chimiques

CCCTC-Binding Factor 0
CTCF protein, human 0
Chromatin 0
ESR1 protein, human 0
Estrogen Receptor alpha 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9557-9572

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of Nucleic Acids Research.

Références

Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Nat Methods. 2012 Oct;9(10):969-72
pubmed: 22961246
Nat Biotechnol. 2016 Feb;34(2):192-8
pubmed: 26751173
J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):85-94
pubmed: 10819507
Mol Cell. 2010 Dec 22;40(6):877-92
pubmed: 21172654
Oncogene. 2015 Jul 23;34(30):3968-76
pubmed: 25284585
Development. 1997 May;124(10):1851-64
pubmed: 9169833
Cancer Res. 2008 Nov 1;68(21):9041-9
pubmed: 18974150
Genome Res. 2013 Aug;23(8):1210-23
pubmed: 23636943
Nucleic Acids Res. 2015 Jan;43(Database issue):D662-9
pubmed: 25352552
PLoS One. 2014 Dec 03;9(12):e113354
pubmed: 25470140
Mol Cell. 2017 Sep 21;67(6):1049-1058.e6
pubmed: 28938092
Mol Cancer Ther. 2007 May;6(5):1526-33
pubmed: 17513601
Nature. 2014 Mar 27;507(7493):455-461
pubmed: 24670763
Science. 2014 Jan 3;343(6166):84-87
pubmed: 24336571
Cell Rep. 2014 May 22;7(4):1020-9
pubmed: 24794443
Nucleic Acids Res. 2016 Dec 15;44(22):10588-10602
pubmed: 27638884
Oncotarget. 2017 Jan 31;8(5):8559-8573
pubmed: 28051998
Nucleic Acids Res. 2018 Sep 6;46(15):e91
pubmed: 29800273
J Biol Chem. 2016 Aug 12;291(33):17258-70
pubmed: 27358402
Breast Cancer Res. 2014 Sep 24;16(5):441
pubmed: 25248717
Dev Biol. 2010 Mar 15;339(2):250-7
pubmed: 20025863
Oncotarget. 2017 Jan 10;8(2):3111-3123
pubmed: 27902972
PLoS Med. 2010 May 25;7(5):e1000279
pubmed: 20520800
Nat Rev Genet. 2010 Jun;11(6):439-46
pubmed: 20442713
Oncogene. 1990 Dec;5(12):1743-53
pubmed: 2284094
Cancer Lett. 2018 Nov 1;436:87-95
pubmed: 30145202
Lancet. 2005 May 14-20;365(9472):1687-717
pubmed: 15894097
Cell. 2015 May 21;161(5):1012-1025
pubmed: 25959774
Bioinformatics. 2011 Dec 15;27(24):3423-4
pubmed: 21949271
Nat Methods. 2015 May;12(5):433-8
pubmed: 25799441
Science. 2008 Dec 19;322(5909):1845-8
pubmed: 19056941
Nat Genet. 2006 Nov;38(11):1289-97
pubmed: 17013392
Cancer Discov. 2016 Aug;6(8):914-29
pubmed: 27260156
Mol Cell. 2015 Nov 19;60(4):676-84
pubmed: 26527277
Cell. 2017 May 4;169(4):693-707.e14
pubmed: 28475897
Nat Genet. 2013 Dec;45(12):1439-45
pubmed: 24185512
Mol Cell. 2003 Mar;11(3):695-707
pubmed: 12667452
BMC Genomics. 2011 Dec 05;12:593
pubmed: 22142239
Science. 2016 Mar 25;351(6280):1454-1458
pubmed: 26940867
Cell. 2013 Mar 14;152(6):1285-97
pubmed: 23498937
Nucleic Acids Res. 2016 Jan 4;44(D1):D938-43
pubmed: 26673713
Autophagy. 2012 Feb 1;8(2):165-76
pubmed: 22248718
Cell. 2017 May 18;169(5):930-944.e22
pubmed: 28525758
Cell. 2014 Oct 9;159(2):374-387
pubmed: 25303531
Endocr Relat Cancer. 2003 Jun;10(2):193-202
pubmed: 12790782
Cell. 2013 Jun 6;153(6):1281-95
pubmed: 23706625
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Nature. 2012 Apr 11;485(7398):381-5
pubmed: 22495304
Cell. 1998 Dec 23;95(7):927-37
pubmed: 9875847
Cell. 2003 Dec 12;115(6):751-63
pubmed: 14675539
Curr Biol. 2011 Mar 8;21(5):406-12
pubmed: 21353562
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Cell. 2011 May 13;145(4):622-34
pubmed: 21549415
Methods. 2009 Jul;48(3):240-8
pubmed: 19275939
EMBO J. 2007 Aug 8;26(15):3534-44
pubmed: 17627277
Nat Biotechnol. 2013 Jul;31(7):615-22
pubmed: 23770639
Nature. 2009 Nov 5;462(7269):58-64
pubmed: 19890323
Annu Rev Genomics Hum Genet. 2006;7:29-59
pubmed: 16719718
Curr Biol. 2010 Sep 14;20(17):R754-63
pubmed: 20833320
Science. 2014 Jan 3;343(6166):80-4
pubmed: 24336569
J Biol Chem. 2010 Sep 10;285(37):28604-13
pubmed: 20610384
Pharmacol Rev. 2006 Dec;58(4):773-81
pubmed: 17132854
Mol Oncol. 2018 Nov;12(11):1884-1894
pubmed: 29972720
Mol Cell. 2013 Mar 7;49(5):773-82
pubmed: 23473598
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Cancer Res. 2013 Nov 15;73(22):6632-41
pubmed: 24242068
Nature. 2012 Apr 11;485(7398):376-80
pubmed: 22495300
Cell. 2017 Jul 27;170(3):577-592.e10
pubmed: 28753431
Mol Endocrinol. 2009 Sep;23(9):1335-45
pubmed: 19477949
Annu Rev Genomics Hum Genet. 2012;13:29-57
pubmed: 22703170
Cell. 2017 Jul 27;170(3):564-576.e16
pubmed: 28753430
Genes Dev. 1987 Nov;1(9):981-95
pubmed: 2892761
BMC Genomics. 2013 Apr 08;14:232
pubmed: 23565824
Mol Cell Biol. 2007 Mar;27(5):1631-48
pubmed: 17210645
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Cell. 2018 May 31;173(6):1398-1412.e22
pubmed: 29731168
Oncogene. 2011 Mar 3;30(9):1059-71
pubmed: 21042280
Nature. 2013 Jun 27;498(7455):516-20
pubmed: 23728302
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925

Auteurs

Gozde Korkmaz (G)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Zohar Manber (Z)

Department of Human Genetics, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.

Rui Lopes (R)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Stefan Prekovic (S)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Karianne Schuurman (K)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Yongsoo Kim (Y)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Hans Teunissen (H)

Division of Gene Regulation, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Koen Flach (K)

Division of Gene Regulation, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Elzo de Wit (E)

Division of Gene Regulation, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Giorgio G Galli (GG)

Disease area Oncology, Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.

Wilbert Zwart (W)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, PO Box 513, 5600MB, Eindhoven, The Netherlands.

Ran Elkon (R)

Department of Human Genetics, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.

Reuven Agami (R)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Erasmus MC, Rotterdam University, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH